Published in Women's Health Weekly, December 23rd, 2010
More than thousand patients and 50 hospitals participated in the study, whose findings are reported in the latest issue of The New England Journal of Medicine. Results indicate that docentaxel during quimotherapy reduces the risk of recurrence by 32% in women with high-risk but node-negative, early stage breast cancer when cancer has not spread to lymph nodes.
The aim of the research was to test...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly